InflaRx IFRX 深 沪
等待开盘 08-19 09:30:00 美东时间
2.18
+0.110
+5.31%
华盛通- 最 高2.18
- 今 开2.05
- 成交量 55.46万股
- 最 低 2.035
- 昨 收 2.07
- 总市值 3.21亿
- 52周最高 2.9489
- 市盈率 静 --
- 换手率 0.38%
- 52周最低 0.7984
- 委 比 0.00%
- 总股本 1.47亿
- 历史最高 53.10
- 量 比 0.46
- 振 幅 7.00%
- 历史最低 0.7113
- 每 手 1
- 风险率 0.49%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
Cantor Fitzgerald Maintains Overweight on InflaRx, Raises Price Target to $6
Cantor Fitzgerald analyst Steve Seedhouse maintains InflaRx (NASDAQ:IFRX) with a Overweight and raises the price target from $4 to $6.
08-07 20:30
Analysts’ Top Healthcare Picks: InflaRx (IFRX), CG Oncology, Inc. (CGON)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts jus...
08-07 05:20
InflaRx Q2 EPS $(0.10) Misses $(0.08) Estimate
InflaRx (NASDAQ:IFRX) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.08) by 25 percent. This is a 58.33 percent increase over losses of $(0.24) per share from the same period last year.
08-06 19:33
InflaRx to Report Second Quarter 2026 Results on August 6, 2026
InflaRx N.V., a biopharmaceutical company developing anti-inflammatory therapies targeting the complement system, will release its Q2 2026 financial and operational results on August 6, 2026, before market open. No conference call is scheduled. The company specializes in C5a and C5aR inhibitors, with lead programs izicopan and vilobelimab for inflammatory diseases. Founded in 2007, InflaRx has offices in Germany and the U.S.
07-30 11:30
InflaRx Mulls Feasibility For AAV In Europe
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it is assessing the feasibility of broadening its development and registrational strategy for AAV in Europe. The company has initiated this assessmen...
06-30 19:37
InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos
InflaRx is evaluating the feasibility of expanding its development and regulatory strategy for ANCA-associated vasculitis (AAV) in Europe following the EMA's recommendation to revoke Tavneos' marketing authorization. The company plans to engage with EMA regarding its anti-C5a antibody vilobelimab and next-generation oral C5aR inhibitor izicopan to assess the most efficient regulatory pathway for approval. Vilobelimab, approved under exceptional c...
06-30 11:30
美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
Cantor Fitzgerald Maintains Overweight on InflaRx, Raises Price Target to $4
Cantor Fitzgerald analyst Steve Seedhouse maintains InflaRx (NASDAQ:IFRX) with a Overweight and raises the price target from $2 to $4.
05-11 21:47
